03/26/2026
We’re deeply grateful for this thoughtful, informative conversation hosted by The Desmoid Tumor Research Foundation- DTRF.
If you missed the recent webinar on desmoid tumor diagnosis and classification, it’s truly worth a watch. The discussion offers meaningful insight into how these distinctions shape both treatment decisions and the experience of living with a desmoid tumor.
We’re especially honored that our own Ashley Williams brought the mental health and lived experience perspective to this multidisciplinary panel.
We’re continually grateful for DTRF’s commitment to providing high-quality education and resources to the desmoid community.
Alongside the mental health and community support offered by The Desmoid Project, partnerships like this reflect what Strength Through Connection truly looks like—ensuring that patients and caregivers have access to both trusted information and meaningful support as they navigate all that comes with a desmoid diagnosis.
🎥 A recording of our recent virtual event, "How Desmoid Tumors are Classified and Why It Matters for Patients" is ready to watch!
📣 Spread the word by sharing this recording with your social networks today: https://vimeo.com/1176968287
💡Desmoid tumors (also known as aggressive fibromatosis, desmoid fibromatosis, and desmoid-type fibromatosis) do not metastasize. They are classified by the World Health Organization (WHO) as “Intermediate (locally aggressive)” soft tissue tumors. They do not fall under “Benign” or “Malignant” classifications. Learn more about desmoid tumors here: https://bit.ly/DTRF-SpreadtheWord-2026
🔗 Learn more about the World Health Organization's (WHO) classification of desmoid tumors, which is listed under Table II: Fibroblastic/Myofibroblastic Tumours: https://pmc.ncbi.nlm.nih.gov/articles/PMC8167394/
⭐ Special thank you to Dr. Gounder, Ashley Williams, LCSW and Dr. Agaram for their willingness to discuss this important topic and answer questions from the desmoid community.
💜 Thank you to our webinar sponsor, SpringWorks Therapeutics, for their continuous support of desmoid tumor educational content.